ClinicalTrials.gg
CompletedNCT03529123Updated Apr 25, 2022

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

A Phase 3 interventional study of INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010) and INSULIN GLARGINE (HOE901) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 13 sites in India. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
89th of 175
247 · median 253
Started
2018
with 6 others
Phase 3
60 of 176
1 open now
Registered
147th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 89th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2018, is one of 60 in phase 3, and was the 147th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine by demonstrating change in glycosylated hemoglobin (HbA1c).

Secondary Objectives:

  • To assess the effects of the FRC in comparison with insulin glargine on:
  • Percentage of patients reaching HbA1c targets (\<7% );
  • Glycemic control in relation to a meal as evaluated by 2-hour Post-prandial Plasma Glucose; (PPG);
  • Body weight
  • Fasting Plasma Glucose (FPG);
  • Percentage of patients reaching HbA1c targets of \<7% with no body weight gain and no hypoglycemia (as defined in the evaluation criteria);
  • 7-point Self-Monitoring Plasma Glucose (SMPG) profile;
  • Insulin glargine dose.
  • To assess the safety and tolerability in each treatment group.
Read the detailed description

The maximum study duration per patient is 33 weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit,
  • At screening:
  • Age should be ≥ 18 years of age to \< 65 years;
  • Glycosylated () at screening visit ≥ 7.5% or ≤ 10%;
  • (BMI) ≥ 19 kg/m2 and ≤ 40 kg/m2.
  • Patients who have been treated with a basal insulin for at least 6 months before the screening visit, and who have been on a stable basal insulin regimen (ie, type of insulin and time/frequency of the injection), for at least 3 months before the screening visit. The stable total daily dose should be within the range of 15-40 U, both inclusive, on the day of screening, but individual fluctuations of ± 20% within 2 months prior to screening are acceptable.

Exclusion criteria

Exclusion criteria:

  • Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria in the 3 months before screening.
  • Previous use of insulin regimen other than basal insulin eg, prandial or pre-mixed insulin (Note: Short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the investigator).
  • For patients taking metformin, any to metformin use, according to local labeling.
  • For patient not treated with metformin at screening: severe renal function impairment with an estimated (eGFR) \<30 mL/min/1.73m2 or end-stage renal disease.
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).
  • history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (ie, worsening) or not controlled (ie, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening visit; or history of surgery affecting gastric emptying.
  • History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
  • Average insulin glargine daily dose \<20 U or >50 U calculated for the last 3 days before Visit 6.
  • Amylase and/or lipase >3 upper limit normal () at Visit 5 (Week -1).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Tested Drug

    Insulin glargine/lixisenatide fixed ratio combination (FRC)

    Drug: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010) · Drug: Metformin · Drug: Insulin Glulisine (HMR1964)

  • Active comparator
    Control Drug

    Insulin glargine (Lantus®)

    Drug: INSULIN GLARGINE (HOE901) · Drug: Metformin · Drug: Insulin Glulisine (HMR1964)

Interventions

  • DrugINSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)

    Drug pages: Insulin Glargine · Lixisenatide

    Pharmaceutical form: Injection Route of administration: Subcutaneous

    Also known as: Soliqua, Insulin Glargine/Lixisenatide Fixed Ratio Combination

  • Pharmaceutical form: Injection Route of administration: Subcutaneous

    Also known as: Lantus®

  • Pharmaceutical form: Tablet Route of administration: Oral

  • Pharmaceutical form: Injection Route of administration: Subcutaneous

    Also known as: Apidra

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Mean change in glycosylated hemoglobin (HbA1c) from baseline to Week 24

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Patients with HbA1c <7%

    Number of patients reaching HbA1c \<7 % at the end of Week 24

    Time frame: At Week 24

  2. Change in 2-hour Post prandial glucose (PPG)

    Change in 2-hour PPG from baseline to Week 24

    Time frame: From baseline to Week 24

  3. Change in body weight

    Change in body weight from baseline to Week 24

    Time frame: From baseline to Week 24

  4. Patients with HbA1c <7% with no body weight gain and no hypoglycemia

    Number of patients reaching HbA1c \<7% with no body weight gain and no hypoglycemia at the end of Week 24

    Time frame: At Week 24

  5. Change in Fasting Plasma Glucose

    Mean change in FPG from baseline to Week 24

    Time frame: From baseline to Week 24

  6. Adverse events (AE)

    Number of AEs

    Time frame: Up to 33 weeks

  7. Patients with HbA1c <7% with no body weight gain

    Number of patients reaching HbA1c \<7% with no body weight gain at the end of Week 24

    Time frame: At Week 24

  8. Change in SMPG profiles

    Change in 7-point self-monitoring plasma glucose (SMPG) profiles from baseline to Week 24

    Time frame: From baseline to Week 24

07

Study locations

13 sites
  • Investigational Site Number 01
    Bangalore, 560092, India
  • Investigational Site Number 012
    Belgaum, 590010, India
  • Investigational Site Number 013
    Chennai, 600086, India
  • Investigational Site Number 017
    Coimbatore, 641009, India
  • Investigational Site Number 06
    Hyderabad, 500063, India
  • Investigational Site Number 07
    Hyderabad, 500072, India
  • Investigational Site Number 08
    Jaipur, India
  • Investigational Site Number 04
    Kolkata, 700107, India
  • Investigational Site Number 018
    Lucknow, India
  • Investigational Site Number 014
    Madurai, 625020, India
  • Investigational Site Number 05
    Nasik, 422002, India
  • Investigational Site Number 010
    New Delhi, 110029, India
  • Investigational Site Number 016
    Pune, 411040, India
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2019, 17 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
May 18, 2018
StartActual
Jun 19, 2018
Primary completionActual
Nov 25, 2019
CompletionActual
Nov 25, 2019
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03529123
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 18, 2018
Start date
Jun 19, 2018
Primary completion
Nov 25, 2019
Completion
Nov 25, 2019
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion